Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumours

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumours including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC), and oesophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in … Continued